Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

100.40 -1.44 (-1.41%)
Official Closing Price Updated: 7:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
3 No-Brainer Growth Stocks to Buy in December
No analysis paralysis is required with these great stocks. 
Via The Motley Fool
Pfizer Tumbles After Abandoning Weight-Loss Pill
With shares already reflecting a post-COVID dearth of revenue streams, Pfizer's growth outlook recently took another hit as it halted development of its experimental weight-loss pill after a high rate... 
Via Talk Markets
Everyone Is Talking About This Stock. Is It a Good Long-Term Option?
This company famously helps manage a prevalent chronic illness. 
Via The Motley Fool
An Important History Lesson for Gene-Editing Investors
Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy. 
Via The Motley Fool
Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
Both of these stocks have been big winners this year. But one could be better positioned to extend that winning streak over the next decade. 
Via The Motley Fool
Advocacy for Wegovy: Denmark Signals Cost-Sharing Talks While Novo Spent Millions On Medical Community For Drug Promotion
Denmark's Health Minister, Sophie Lohde, has signaled the government's willingness to expand coverage for Novo Nordisk A/S's (NYSE: NVO) weight-loss drug Wegovy if the company shares some of the... 
Via Benzinga
Will NOVO-NORDISK A/S-SPONS ADR breakout?
The technical analysis for NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is highly positive, with a rating of 10 out of 10, suggesting a potential breakout. 
Via Chartmill
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
Via Benzinga
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies... 
Via Benzinga
Weight Loss Drugs - Novo Nordisk A Primary Beneficiary In Obesity Space Currently Controlled By Two Players, Says Analyst
Cantor Fitzgerald has initiated coverage on Europe's most valuable company, Novo Nordisk A/S (NYSE: NVO). 
Via Benzinga
Pfizer Halts Development Of Twice-Daily Weight-Loss Drug; PFE Stock Slides
Pfizer said Friday it would not advance development of a twice-daily oral weight-loss drug because of its side effects. PFE stock fell. 
Via Investor's Business Daily
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Software earnings were strong, while the Fed is shifting toward rate cuts. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Pfizer’s Stock Is Down 44% YTD As Woes Continue
Pfizer's shares plunged on Friday after the drugmaker halted the trial of its twice-daily obesity drug. 
Via Talk Markets
Will Novo Nordisk Be a Trillion-Dollar Stock by 2030?
Novo Nordisk stock has been a red-hot buy this year -- can it continue that trend through this decade? 
Via The Motley Fool
Novo Nordisk Sues Florida Compounding Pharmacies Over Impurities In Products Claiming To Contain Wegovy Ingredient
Novo Nordisk A/S (NYSE: NVO) has reportedly taken legal action against Florida compounding pharmacies, suing one and refiling a lawsuit against another, as it discovered impurities in their products... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Eli Lilly's Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?
Electronic health records say tirzepatide, the active ingredient in Mounjaro and Zepbound, is better at reducing weight than semaglutide, the active ingredient in Ozempic and Wegovy. 
Via The Motley Fool
Counterfeit Ozempic Raises Alarms - Lebanon Reports Hypoglycemia Cases
Lebanese health officials have reported eleven cases of severe hypoglycemia linked to suspected fake versions of Novo Nordisk A/S's (NYSE: NVO)  
Via Benzinga
Watch the buy range for Li Auto, MongoDB, Novo Nordisk
Large-cap stocks Li Auto, MongoDB, and Novo Nordisk are in buy range as the S&P 500 rallies. Those stocks boast robust upside momentum in recent weeks 
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities
Ozempic Receives Some Very Bad News: Is It Time to Sell Novo Nordisk Stock?
Real-world data showed some real-world advantages for Ozempic's top rival. 
Via The Motley Fool
Lilly's Weight-Loss Drug Wallops Novo's In Head-To-Head Study; Novo Stock Dives
The study examined health care records for more than 41,000 people. 
Via Investor's Business Daily
Eli Lilly's Blockbuster Mounjaro Shows Larger, Faster Weight Loss Than Novo Nordisk's Ozempic In Real World Study
A recent extensive analysis by Truveta Research has  
Via Benzinga
Only Have $100? 3 No-Brainer Stocks to Buy Right Now
The stock market is such a well-oiled, wealth-generating machine that investors can start with just $100 to buy these no-brainer stocks. 
Via InvestorPlace
Novo Nordisk's Flexible Pricing Approach: Push for Broader Access, Innovative Payments
Novo Nordisk A/S (NYSE: NVO) is reportedly discussing with healthcare systems to introduce innovative pricing arrangements for its popular weight  
Via Benzinga
BellRing Brands gets pumped on the Ozempic weight-loss trend
Sports nutritional products maker BellRing Brands Inc. (NYSE: BRBR) has seen its stock surge to new all-time highs driven by the popularity of GLP-1 weight-loss 
Via MarketBeat
Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?
An upcoming mid-stage readout may not spark a trend reversal in the big pharma's shares. 
Via The Motley Fool
Google Leads Five S&P 500 Stocks Near Buy Points
Four of the stocks tripped up after earnings, but quickly bounced back. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Could Ozempic Harm These 3 Medical Device Stocks?
The drug is on track to cause massive competitive shifts in the healthcare sector. 
Via The Motley Fool
Novo Nordisk's Wegovy Eyes Asian Market Debut Despite Supply Crunch
Novo Nordisk A/S (NYSE: NVO) reportedly plans to introduce its highly sought-after anti-obesity medication, Wegovy, in Japan on February 22, marking its inaugural entry into the Asian market despite... 
Via Benzinga
7 Stocks Set to Capitalize on the Coming Year-End Rally
The stock market is poised to rally at the year end as multiple positive factors conspire to push certain sectors higher. 
Via InvestorPlace
$3,000 Invested in These 3 Top Stocks Could Make You Rich in 10 Years
Plug into a trio of megatrends with these three particular tickers. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback